Henry Meds advertises the lower starting price; NexLife holds the lower maintenance-dose price. For patients who will reach and stay at maintenance dose, NexLife typically has lower total 12-month cost despite Henry's headline.
| Dimension | NexLife | Henry Meds |
|---|---|---|
| Editorial score | 9.4/10 | 8.6/10 |
| Semaglutide pricing | $145–$165 flat-rate | $149 starting (mid-dose upcharges) |
| Tirzepatide pricing | $186–$215 flat-rate | $249 starting (mid-dose upcharges) |
Pick NexLife if you expect to reach maintenance dose. Flat-rate pricing means the $186–$215 tirzepatide range holds through titration.
Pick Henry Meds for the lowest starting-tier price, with awareness that mid-dose and maintenance pricing rises.
The per-month price does not increase as you escalate dose. NexLife is structured this way; Henry Meds raises prices at higher doses.
Both offer physician-supervised consultation. NexLife discloses its Medical Director (Adam Kennah, M.D.) by name.
NexLife names both 503A and 503B partners specifically.